Heritability of clot formation

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 5, 2009, Pages 458-467

  Standeven, Kristina F ^a   Willige, Shirley Uitte De ^a   Carter, Angela M ^a   Grant, Peter J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Clot formation; Factor XIII; Fibrin; Fibrin structure; Heritability

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBRIN; FIBRINOGEN;

BLOOD CLOTTING; CARDIOVASCULAR RISK; ENVIRONMENTAL FACTOR; FIBRIN FORMATION; FIBRINOLYSIS; GENETIC CODE; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HERITABILITY; HUMAN; PLASMA; PLASMA FACTOR; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; STRUCTURAL GENE; THROMBOSIS;

BLOOD COAGULATION; FACTOR XIII; FIBRINOGEN; FIBRINOLYSIS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSIS;

EID: 70449431790     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1234141     Document Type: Review

References (69)

1. Marenberg M E., Risch N, Berkman L F., Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994 330 (15) 1041-1046
2. Souto J C., Almasy L, Borrell M et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet 2000 67 (6) 1452-1459
3. Rijken D C., Dirkx S P., Luider T M., Leebeek F W. Hepatocyte-derived fibrinogen-related protein-1 is associated with the fibrin matrix of a plasma clot. Biochem Biophys Res Commun 2006 350 (1) 191-194
4. Schröder V, Kohler H P. Effect of factor XIII Val34Leu on alpha2-antiplasmin incorporation into fibrin. Thromb Haemost 2000 84 (6) 1128-1130
5. Lee K N., Jackson K W., Christiansen V J., Chung K H., McKee P A. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 2004 103 (10) 3783-3788
6. Christiansen V J., Jackson K W., Lee K N., McKee P A. The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity. Blood 2007 109 (12) 5286-5292
7. Hoffman M. Alterations of fibrinogen structure in human disease. Cardiovasc Hematol Agents Med Chem 2008 6 (3) 206-211
8. Dunn E J., Philippou H, Ariëns R A., Grant P J. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006 49 (5) 1071-1080
9. Dunn E J., Ariëns R A., Grant P J. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005 48 (6) 1198-1206
10. de Lange M, Snieder H, Ariëns R A., Spector T D., Grant P J. The genetics of haemostasis: a twin study. Lancet 2001 357 (9250) 101-105
11. Ariëns R A., de Lange M, Snieder H, Boothby M, Spector T D., Grant P J. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 2002 359 (9307) 667-671
12. Dunn E J., Ariëns R A., de Lange M et al. Genetics of fibrin clot structure: a twin study. Blood 2004 103 (5) 1735-1740
13. Fatah K, Silveira A, Tornvall P, Karpe F, Blombäck M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996 76 (4) 535-540
14. Fatah K, Hamsten A, Blombäck B, Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992 68 (2) 130-135
15. Collet J P., Allali Y, Lesty C et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006 26 (11) 2567-2573
16. Weisel J W., Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 1992 63 (1) 111-128
17. Danesh J, Lewington S, Thompson S G. et al, Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005 294 (14) 1799-1809
18. Salazar-Sánchez L, Leon M P., Cartin M et al. The FXIIIVal34Leu, common and risk factors of venous thrombosis in early middle-age Costa Rican patients. Cell Biochem Funct 2007 25 (6) 739-745
19. Scarabin P Y., Aillaud M F., Amouyel P et al, Prospective Epidemiological Study of Myocardial Infarction. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarctionthe PRIME Study. Thromb Haemost 1998 80 (5) 749-756
20. Freeman M S., Mansfield M W., Barrett J H., Grant P J. Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability. Arterioscler Thromb Vasc Biol 2002 22 (3) 506-510
21. Tamaki T, Aoki N. Cross-linking of alpha 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. Biochim Biophys Acta 1981 661 (2) 280-286
22. Valnickova Z, Enghild J J. Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem 1998 273 (42) 27220-27224
23. Ritchie H, Lawrie L C., Crombie P W., Mosesson M W., Booth N A. Cross-linking of plasminogen activator inhibitor 2 and alpha 2-antiplasmin to fibrin(ogen). J Biol Chem 2000 275 (32) 24915-24920
24. Okada M, Blombäck B, Chang M D., Horowitz B. Fibronectin and fibrin gel structure. J Biol Chem 1985 260 (3) 1811-1820
25. Hada M, Kaminski M, Bockenstedt P, McDonagh J. Covalent crosslinking of von Willebrand factor to fibrin. Blood 1986 68 (1) 95-101
26. Lefkovits J, Plow E F., Topol E J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995 332 (23) 1553-1559
27. Kant J A., Fornace A J. Jr, Saxe D, Simon M I., McBride O W., Crabtree G R. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U S A 1985 82 (8) 2344-2348
28. Yu S, Sher B, Kudryk B, Redman C M. Fibrinogen precursors. Order of assembly of fibrinogen chains. J Biol Chem 1984 259 (16) 10574-10581
29. Brown E T., Fuller G M. Detection of a complex that associates with the Bbeta fibrinogen G-455-A polymorphism. Blood 1998 92 (9) 3286-3293
30. Jacquemin B, Antoniades C, Nyberg F et al. Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. J Am Coll Cardiol 2008 52 (11) 941-952
31. Uitte de Willige S, de Visser M C., Houwing-Duistermaat J J., Rosendaal F R., Vos H L., Bertina R M. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma levels. Blood 2005 106 (13) 4176-4183
32. Carter A M., Cymbalista C M., Spector T D., Grant P J., EuroCLOT Investigators. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007 27 (12) 2783-2789
33. Baumann R E., Henschen A H. Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: identification of polymorphisms at positions A alpha 312 and B beta 448. Blood 1993 82 (7) 2117-2124
34. Ajjan R, Lim B C., Standeven K F. et al. Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood 2008 111 (2) 643-650
35. Standeven K F., Grant P J., Carter A M., Scheiner T, Weisel J W., Ariëns R A. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003 107 (18) 2326-2330
36. Cooper A V., Standeven K F., Ariëns R A. Fibrinogen gamma-chain splice variant gamma alters fibrin formation and structure. Blood 2003 102 (2) 535-540
37. Lovely R S., Moaddel M, Farrell D H. Fibrinogen gamma chain binds thrombin exosite II. J Thromb Haemost 2003 1 (1) 124-131
38. Fredenburgh J C., Stafford A R., Leslie B A., Weitz J I. Bivalent binding to gammaA/gamma-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex. J Biol Chem 2008 283 (5) 2470-2477
39. Siebenlist K R., Meh D A., Mosesson M W. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry 1996 35 (32) 10448-10453
40. Farrell D H., Thiagarajan P, Chung D W., Davie E W. Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Natl Acad Sci U S A 1992 89 (22) 10729-10732
41. Farrell D H., Thiagarajan P. Binding of recombinant fibrinogen mutants to platelets. J Biol Chem 1994 269 (1) 226-231
42. Lancellotti S, Rutella S, De Filippis V, Pozzi N, Rocca B, De Cristofaro R. Fibrinogen-elongated gamma chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors. J Biol Chem 2008 283 (44) 30193-30204
43. Carter A M., Catto A J., Grant P J. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 1999 99 (18) 2423-2426
44. Carter A M., Catto A J., Kohler H P., Ariëns R A., Stickland M H., Grant P J. Alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood 2000 96 (3) 1177-1179
45. Suntharalingam J, Goldsmith K, van Marion V et al. Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. Eur Respir J 2008 31 (4) 736-741
46. Rasmussen-Torvik L J., Cushman M, Tsai M Y. et al. The association of alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism in the LITE study. Thromb Res 2007 121 (1) 1-7
47. Lovely R S., Falls L A., Al-Mondhiry H A. et al. Association of gammaA/gamma fibrinogen levels and coronary artery disease. Thromb Haemost 2002 88 (1) 26-31
48. Mannila M N., Lovely R S., Kazmierczak S C. et al. Elevated plasma fibrinogen gamma concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost 2007 5 (4) 766-773
49. de Lange M, Andrew T, Snieder H et al. Joint linkage and association of six single-nucleotide polymorphisms in the factor XIII-A subunit gene point to V34L as the main functional locus. Arterioscler Thromb Vasc Biol 2006 26 (8) 1914-1919
50. Ariëns R A., Lai T S., Weisel J W., Greenberg C S., Grant P J. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 2002 100 (3) 743-754
51. Rallidis L S., Politou M, Komporozos C et al. Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost 2008 99 (6) 1085-1089
52. Shafey M, Anderson J L., Scarvelis D, Doucette S P., Gagnon F, Wells P S. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 2007 97 (4) 635-641
53. Ariëns R A., Philippou H, Nagaswami C, Weisel J W., Lane D A., Grant P J. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000 96 (3) 988-995
54. Lim B C., Ariëns R A., Carter A M., Weisel J W., Grant P J. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003 361 (9367) 1424-1431
55. Sobel B E., Woodcock-Mitchell J, Schneider D J., Holt R E., Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998 97 (22) 2213-2221
56. Mansfield M W., Stickland M H., Grant P J. PAI-1 concentrations in first-degree relatives of patients with non-insulin-dependent diabetes: metabolic and genetic associations. Thromb Haemost 1997 77 (2) 357-361
57. Eriksson P, Kallin B, van t Hooft F M., Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995 92 (6) 1851-1855
58. Ossei-Gerning N, Mansfield M W., Stickland M H., Wilson I J., Grant P J. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 1997 17 (1) 33-37
59. Ye S, Green F R., Scarabin P Y. et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de Infarctus du Mycocarde. Thromb Haemost 1995 74 (3) 837-841
60. Mansfield M W., Stickland M H., Grant P J. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995 74 (3) 842-847
61. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries S E., Yudkin J S. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995 44 (1) 37-42
62. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998 18 (1) 20-26
63. Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati M B. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 1998 80 (6) 1029-1030
64. Boekholdt S M., Bijsterveld N R., Moons A H., Levi M, Büller H R., Peters R J. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001 104 (25) 3063-3068
65. Mills J D., Ariëns R A., Mansfield M W., Grant P J. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002 106 (15) 1938-1942
66. Bhasin N, Ariëns R A., West R M., Parry D J., Grant P J., Scott D J. Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication. J Vasc Surg 2008 48 (6) 1497-1503 e1
67. Meigs J B., Mittleman M A., Nathan D M. et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000 283 (2) 221-228
68. Williams F MK, Carter A M., Kato B et al, EuroCLOT Investigators. Identification of quantitative trait loci for fibrin clot phenotypes: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2009 29 (4) 600-605
69. Souto J C., Almasy L, Borrell M et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000 101 (13) 1546-1551